The Importance of Offering Genetic Counseling and Testing to All Persons Diagnosed With Frontotemporal Degeneration Spectrum Disorders
Neurology
.
2025 Aug 12;105(3):e213814.
doi: 10.1212/WNL.0000000000213814.
Epub 2025 Jul 18.
Authors
Laynie Dratch
1
,
Kim Jenny
2
,
Kristiana Salmon
3
,
Ashley Crook
4
,
Wendy R Uhlmann
5
,
Jamie C Fong
6
,
Jill S Goldman
7
,
Victoria Klee
8
,
Rhona MacLeod
9
,
Amina Chaouch
10
11
,
Diane E Lucente
12
,
Sarah K Mantia
13
,
Jennifer Pagano
14
,
Weiyi Mu
15
Affiliations
1
Penn Frontotemporal Degeneration Center and Department of Neurology, University of Pennsylvania, Philadelphia.
2
The Association for Frontotemporal Degeneration, King of Prussia, PA.
3
Unaffiliated, Toronto, Canada.
4
Macquarie University MND Research Centre, Macquarie University, Sydney, New South Wales, Australia.
5
Department of Clinical Genetics, Austin Health Australia, Heidelberg, Victoria, Australia.
6
Division of Genetic Medicine, Department of Internal Medicine and Department of Human Genetics, University of Michigan, Ann Arbor.
7
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX.
8
Department of Neurology, University of California-San Francisco, CA.
9
Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY.
10
Division of Human Genetics, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus.
11
Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, United Kingdom.
12
Manchester Clinical Centre for Neurosciences, United Kingdom.
13
School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom.
14
Center for Genomic Medicine, Department of Neurology, Massachusetts General Hospital, Boston.
15
Department of Clinical Genomics, Mayo Clinic, Jacksonville, FL.
PMID:
40680239
DOI:
10.1212/WNL.0000000000213814
No abstract available